|
Nephrology
Insufficient early renal recovery and progression to subsequent chronic kidney disease in living kidney donors
Yaerim Kim, Eunjeong Kang, Dong-Wan Chae, Jung Pyo Lee, Sik Lee, Soo Wan Kim, Jang-Hee Cho, Miyeun Han, Seungyeup Han, Yong Chul Kim, Dong Ki Kim, Kwon Wook Joo, Yon Su Kim, Hajeong Lee
Korean J Intern Med. 2022;37(5):1021-1030. Published online April 13, 2022
Background/Aims: Renal recovery of a kidney donor after undergoing nephrectomy though challenging is essential. We aimed to examine the effect of estimated glomerular filtration rate (eGFR) percent change at 1-month post-donation on insufficient kidney function after kidney donation.
Methods: A tot..
|
|
|
Time points for obtaining representative values of 24-hour blood pressure in chronic kidney disease
Jiwon Ryu, Ran-hui Cha, Dong Ki Kim, Ju Hyun Lee, Sun Ae Yoon, Dong Ryeol Ryu, Jieun Oh, Sejoong Kim, Sang-Youb Han, Eun Young Lee, Yon Su Kim
Korean J Intern Med. 2015;30(5):665-674. Published online August 27, 2015
Background/Aims: Ambulatory blood pressure (BP) monitoring has been widely recommended for evaluating the status of BP, but is lacking in practicality. Determination of the specific time points for BP measurement that are representative of 24-hour mean BP could be useful and convenient in hypertensi..
|
|
|
Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea
Seon Ha Baek, Hyunsuk Kim, Jeonghwan Lee, Dong Ki Kim, Kook-Hwan Oh, Yon Su Kim, Jin Suk Han, Tae Min Kim, Se-Hoon Lee, Kwon-Wook Joo
Korean J Intern Med. 2014;29(1):40-48. Published online January 2, 2014
Background/Aims: Sunitinib is an oral multitargeted tyrosine kinase inhibitor
used mainly for the treatment of metastatic renal cell carcinoma. The renal adverse
effects (RAEs) of sunitinib have not been investigated. The aim of this study
was to determine the incidence and risk factors of RAEs (..
|
|
|
